NYSE · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · LARGE CAP
Edwards Lifesciences Corp. EW
18 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 6.1B
Revenue, FY2025 · full 18-year series below
Revenue $B
Net income $B
FY2025 · Revenue 6.1 · Net income 1.1
Compound annual growth
+10.8%
+6.7%
+9.3%
+10.0%
−11.0%
−9.1%
+7.1%
−21.5%
+8.0%
+14.0%
+9.7%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +6.7% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
18 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 20.8% · Net 17.6%
ROE
FY2025 · ROE 10.6%
Each USD of equity produced 11 cents of profit this year.
The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 6.1 | 5.4 | 5.0 | 4.5 | 5.2 | 4.4 | 4.3 | 3.7 | 3.4 | 3.0 | 2.5 | 2.3 | 2.0 | 1.9 | 1.7 | 1.4 | 1.3 | 1.2 |
| Operating income $B | 1.3 | 1.4 | 1.3 | 1.5 | 1.7 | 0.9 | 1.1 | 0.7 | 1.1 | 0.8 | · | · | · | · | · | · | · | · |
| EBITDA $B | 1.4 | 1.5 | 1.5 | 1.6 | 1.8 | 1.0 | 1.2 | 0.8 | 1.2 | 0.8 | · | · | · | · | · | · | · | · |
| Income tax $B | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.5 | 0.2 | 0.1 | 0.3 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 |
| Net income $B | 1.1 | 4.2 | 1.4 | 1.5 | 1.5 | 0.8 | 1.0 | 0.7 | 0.6 | 0.6 | 0.5 | 0.8 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 |
| Free cash flow $B | 1.3 | 0.3 | 0.6 | 1.0 | 1.4 | 0.6 | 0.9 | 0.7 | 0.8 | 0.5 | 0.4 | 0.9 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 |
| EPS, diluted $ | 1.83 | 6.97 | 2.30 | 2.44 | 2.38 | 1.30 | 1.64 | 1.13 | 2.70 | 2.61 | 2.25 | 3.74 | 1.71 | 2.46 | 1.98 | 1.83 | 1.95 | 1.10 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 10.6 | 50.2 | 22.5 | 26.1 | 28.9 | 18.9 | 28.7 | 23.7 | 20.9 | 22.2 | 21.1 | 43.4 | 25.8 | 20.9 | 18.0 | 17.7 | 22.5 | 14.7 |
| Shares out B | 0.58 | 0.59 | 0.60 | 0.61 | 0.62 | 0.62 | 0.21 | 0.21 | 0.21 | 0.21 | 0.22 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.06 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 88 reconciliationsAUDITED
Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2008